{
    "clinical_study": {
        "@rank": "134384", 
        "arm_group": [
            {
                "arm_group_label": "Group 1", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects (group 1) will be treated daily for their solar lentigines with the investigational drug (Tri-Luma\u00ae cream) for 2 weeks.Then, at week 2, all the subjects will have the solar lentigines treated by cryotherapy (CRY-AC3\u00ae device).\nPost-procedure phase (From week 2 up to Week 13 - Visit ) - Topical antibiotic treatment phase (from week 2 up to Week 5 -  visit 2 up to visit 3): At week 2, all the subjects will start to apply a topical antibiotic (Neomycin/Nebacetin\u00ae ointment) for the next 3 weeks.\n- Tri-Luma\u00ae cream treatment phase (from week 5 up to week 13 - visit 3 up to visit 5): The investigational drug (Tri-Luma\u00ae cream) will be applied again (group 1) for a minimum of 4 weeks and up to 8 weeks, according to the Global Improvement of solar lentigines and absence of PIH."
            }, 
            {
                "arm_group_label": "Group 2", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Subjects (group 2) will be treated daily for their solar lentigines only with sumscreen for 2 weeks.Then, at week 2, all the subjects will have the solar lentigines will be treated by cryotherapy (CRY-AC3\u00ae device).\nPost-procedure phase (From week 2 up to Week 13 - Visit )\n- Topical antibiotic treatment phase (from week 2 up to Week 5 -  visit 2 up to visit 3): At week 2, all the subjects will start to apply a topical antibiotic (Neomycin/Nebacetin\u00ae ointment) for the next 3 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate safety and efficacy of Tri-Luma\u00ae cream as an adjunctive treatment to cryotherapy\n      when used in the pre- and post-procedure phases for the treatment of solar lentigines on the\n      back of the hands and in the prevention of post-inflammatory hyperpigmentation after\n      cryotherapy."
        }, 
        "brief_title": "A Fixed Triple Combination Cream for Solar Lentigines Associated to Cryotherapy", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "condition": "Solar Lentigines", 
        "condition_browse": {
            "mesh_term": "Lentigo"
        }, 
        "detailed_description": {
            "textblock": "To evaluate safety and efficacy of Tri-Luma\u00ae cream as an adjunctive treatment to cryotherapy\n      when used in the pre- and post-procedure phases for the treatment of solar lentigines on the\n      back of the hands and in the prevention of post-inflammatory hyperpigmentation after\n      cryotherapy.\n\n      The study has 13 weeks for each subject. Five visits will take place: at Baseline, week 2,\n      5, 9 and 13 after the cryotherapy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject agreement to provide written informed consent and the willingness and ability\n             to comply with all aspects of the protocol;\n\n          -  Female and male subjects;\n\n          -  Phototype II to IV;\n\n          -  Subjects aged between 40 and 65 years;\n\n          -  Subjects presenting at least 5 lesions of solar lentiges at the back hands with al\n             least 3mm of diameter\n\n          -  History of post-inflammatory hyperpigmentation on body or face\n\n          -  Medical history and physical examination which, based on the investigator's opinion,\n             do not prevent the subject from taking part in the study or from making use of the\n             products under investigation;\n\n          -  Subjects of childbearing age should present a negative urine pregnancy test at\n             baseline and should be using a highly effective contraceptive method during all\n             study;\n\n          -  Availability of the subject throughout the study;\n\n          -  Subject agreeing not to undergo other cosmetic or dermatological procedures during\n             the participation in the study;\n\n          -  Subjects with sufficient schooling and knowledge to enable them to cooperate to the\n             degree required by the protocol.\n\n        Exclusion Criteria:\n\n          -  Pregnant women or women intending to become pregnant in the following 5 months after\n             screening;\n\n          -  Lactation period;\n\n          -  Subjects participating in other clinical trials;\n\n          -  Any prior cosmetic procedures, including fillers, or scars that may interfere with\n             the study results;\n\n          -  Subjects with neoplastic, muscular or neurological diseases;\n\n          -  Subjects with inflammation or active infection in the area to be studied;\n\n          -  Subjects with a history of adverse effects, such as sensitivity to the components of\n             any of the study drug formula,\n\n          -  Subjects with a history of non-adherence to medical treatment or showing\n             unwillingness to adhere to the study protocol;\n\n          -  Any condition that, in the opinion of the investigator, can compromise the evaluation\n             of the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01778179", 
            "org_study_id": "2012-03"
        }, 
        "intervention": {
            "arm_group_label": "Group 1", 
            "description": "Pre-procedure phase (From Baseline up to Week 2)treated daily for their solar lentigines with the investigational drug (Tri-Luma\u00ae cream) for 2 weeks.\nPost-procedure phase (From week 2 up to Week 13 - Visit )\n- Tri-Luma\u00ae cream treatment phase (from week 5 up to week 13 - visit 3 up to visit 5):The investigational drug (Tri-Luma\u00ae cream) will be applied again (group 1) for a minimum of 4 weeks and up to 8 weeks, according to the Global Improvement of solar lentigines and absence of PIH.", 
            "intervention_name": "Tri-luma", 
            "intervention_type": "Drug", 
            "other_name": "Tri-luma"
        }, 
        "intervention_browse": {
            "mesh_term": "Fluocinolone Acetonide"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Lentigines", 
            "Cryotherapy", 
            "hyperpigmentation"
        ], 
        "lastchanged_date": "January 25, 2013", 
        "number_of_arms": "2", 
        "official_title": "SAFETY AND EFFICACY OF A FIXED TRIPLE COMBINATION CREAM (FLUOCINOLONE ACETONIDE 0.01%, HYDROQUINONE 4%, TRETINOIN 0.05%) AS ADJUVANT TREATMENT OF SOLAR LENTIGINES WITH CRYOTHERAPY", 
        "overall_official": {
            "affiliation": "Brazilian Center for Studies in Dermatology", 
            "last_name": "Doris Hexsel, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Brazil: National Committee of Ethics in Research", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Solar lentigines count at each visit, up to 13 weeks", 
            "measure": "Solar lentigines count at each visit", 
            "safety_issue": "No", 
            "time_frame": "up to 13 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01778179"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Brazilan Center for Studies in Dermatology", 
            "investigator_full_name": "Doris Hexsel", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "scale of 4 points for post-inflammatory hyperpigmentation", 
            "measure": "Severity of Post-inflammatory hyperpigmentation", 
            "safety_issue": "No", 
            "time_frame": "up to 13 weeks"
        }, 
        "source": "Brazilan Center for Studies in Dermatology", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Brazilan Center for Studies in Dermatology", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "January 2012"
    }
}